Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

DISCUSSION: LC analysis indicates that amyloid reduction is associated with improved clinical outcomes and supports its use as a surrogate biomarker in clinical trials.HIGHLIGHTS: We used latent class (LC) analysis to test amyloid reduction as a surrogate biomarker. Despite similar baseline characteristics, the amyloid-reduction class exhibited remarkably better outcomes compared to the amyloid-growth class across multiple measures. LC analysis proves valuable in testing amyloid reduction as a surrogate biomarker in clinical trials lacking significant treatment effects.PMID:38400532 | DOI:10.1002/alz.13735

Source: The Journal of Alzheimers Association - February 24, 2024 Category: Psychiatry Authors: Guoqiao Wang Yan Li Chengjie Xiong Tammie L S Benzinger Brian A Gordon Jason Hassenstab Andrew J Aschenbrenner Eric McDade David B Clifford Jorge J Libre-Guerra Xinyu Shi Catherine J Mummery Christopher H van Dyck James J Lah Lawrence S Honig Gregg Day Jo Source Type: research